NCT07536282尚未招募1 期
A Phase I/IIa, Randomized, Double Blind, Placebo Controlled, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of NWRD09 Injection in Female Participants With Persistent HPV16 Infection
Newish Biotech (Wuxi) Co., Ltd.1 个研究点 分布在 1 个国家目标入组 78 人开始时间: 2026年10月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 78
- 试验地点
- 1
- 主要终点
- Incidence and severity of local and systemic adverse events (AEs).
研究概览
简要总结
This is a two-part, phase I/IIa study, intended to evaluate the safety, tolerability, immunogenicity, and efficacy of NWRD09 in female participants with persistent HPV16 infection, and to determine the MTD, and/or RP2D of NWRD09.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Participants who have fully understood the study, able and willing to comply with all study procedures, and voluntarily sign written ICF;
- •Female participants aged 18-60 years (inclusive) at the time of signing the ICF;
- •Persistent HPV16 infection, defined as virologically confirmed HPV16 positivity persisting for ≥ 6 months before screening (e.g., participants must provide investigator-approved evidence of HPV16 infection ≥ 6 months prior to screening and be HPV16 positive at the time of screening);
- •Participants must have a confirmed cytological results of atypical squamous cells cannot exclude high-grade squamous intraepithelial lesion (ASC-H) or high-grade squamous intraepithelial lesion (HSIL) at the time of screening (histopathological confirmed cervical/vaginal/vulvar LSIL are acceptable but not required);
- •Satisfactory colposcopy at screening;
- •Normal major organ functions at screening;
- •Women of child-bearing potential must have a negative serum pregnancy test result at screening. All WOCBP participants agree to voluntarily use effective contraception, from signing the ICF to the end of the study. In addition, female participants must agree not to donate eggs during this period.
排除标准
- •Histopathological confirmed high-grade cervical, vulvar, vaginal or anal intraepithelial lesions (including endocervical adenocarcinoma-in-situ [AIS]) or invasive cancer, OR cervical cytology results showing squamous cell carcinoma (SCC), atypical glandular cells (AGC), or AIS at screening;
- •Negative for HPV16 as confirmed by real-time quantitative polymerase chain reaction (RT-qPCR) at screening;
- •Comorbid infectious diseases, such as acute pelvic inflammatory disease, urinary tract infection, or other active infections requiring systemic treatment prior to the first injection;
- •Participants with unresolved vaginal/cervical conditions prior to the first injection that could affect clinical response (e.g., common sexually transmitted infections such as gonorrhoea, genital herpes, etc.);
- •Positive serological test results at screening for human immunodeficiency virus (HIV), treponema pallidum antibody, or hepatitis B virus surface antigen (HBsAg) positive; or hepatitis C virus antibody (HCV-Ab) positive and hepatitis C virus (HCV) ribonucleic acid (RNA) quantitative > the lower limit of the positive detection value of the study site;
- •Significant abnormalities at the screening ECG, including QTc interval > 470 msec (average of triplicate measurements corrected for heart rate using Fridericia's formula), or history/presence of clinical symptoms of cardiac diseases that is not well controlled, such as New York Heart Association (NYHA) Class 2 or higher heart failure, unstable angina, myocardial infarction within the past 6 months, and clinically significant supraventricular or ventricular arrhythmia requiring treatment or intervention;
- •Systemic corticosteroid use (e.g., > 10 mg/day prednisone for > 1 week) within 30 days before screening, excluding hormone replacement therapy and local/topical use (e.g., ocular, intratracheal);
- •Immunosuppressant use (> 1 week) within 30 days or 5 drug half-lives (whichever is longer) before screening (including but not limited to cyclosporine, tacrolimus, azathioprine, 6-mercaptopurine, or antilymphocyte globulin);
- •Current or planned use of disease-modifying antirheumatic drugs (DMARDs, e.g., azathioprine, cyclophosphamide, cyclosporine, methotrexate) or biologic DMARDs (e.g., infliximab, adalimumab, etanercept) during the study;
- •Received any vaccine (other than HPV prophylactic vaccines) within 8 weeks before screening or plan to receive any vaccine during the study;
- •History of therapeutic HPV vaccination.
研究组 & 干预措施
Placebo
Placebo Comparator
干预措施: Placebo (Biological)
NWRD09
Experimental
Predefined dose groups of NWRD09
干预措施: NWRD09 (Biological)
结局指标
主要结局
Incidence and severity of local and systemic adverse events (AEs).
时间窗: Up to Week 28
Adverse events (AEs) and serious adverse events (SAEs) will be monitored based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0.
次要结局
- T cell responses to the separate or combined protein peptide pools of HPV16 E1, E2, E6 and E7 proteins(Weeks 6, 16 and 28)
- Serum HPV16 E6/E7-specific IgG antibodies will be determined by ELISA(Weeks 6, 16 and 28)
- Proportion of participants with clearance of HPV16(Weeks 16 and 28)
- Proportion of participants with cervical cytology normal/ASC-US/LSIL(Week 16 and 28)
- For participants with histopathological LSIL at baseline, proportion of participants with histopathological regression to NSIL(Week 28)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
A Trial of SHR-2173 in Healthy VolunteersNCT07390747Atridia Pty Ltd.18
招募中
1 期
SA1211 Injection Phase 1 StudyNCT07275918Suzhou Siran Biotechnology Co.,Ltd.80
招募中
1 期
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of ABBV-243 in Healthy Adults.NCT07306754AbbVie66
招募中
2 期
A Phase 2 Safety, Tolerability, PK, and Efficacy Study of CS-1103 Following Fentanyl Challenge With Naloxone BlockadeNCT07459166Clear Scientific, Inc.16
招募中
2 期
Study to Assess Efficacy and Safety of HSK39297 Tablets in Patients With LNNCT07363460Haisco Pharmaceutical Group Co., Ltd.105